AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04817566 — intervention group
Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Intensive cognitive training
Description: Intensive cognitive training of a letter memory updating task, 9 sessions for approximately 20 min
Study NCT04817566 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intensive cognitive training
Description: Intensive cognitive training of a letter memory updating task, 9 sessions for approximately 20 min
Study NCT05410691 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Handheld US device
Description: Handheld US-guided AVF/AVG cannulation
Study NCT05175053 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Renal replacement therapy
Description: Continuous renal replacement therapy using continuous venovenous hemodiafiltration (CVVHDF)
Study NCT05175053 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Best medical management
Description: The best medical management continues until the patient meets absolute indication of renal replacement therapy
Study NCT04865146 — intervention group
Intervention type: DEVICE
Intervention: TRIGEN™ INTERTAN™
Description: Femoral fracture treated with INTERTAN 10S Nail
Study NCT05900765 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zimberelimab 240mg
Description: AVD regimen:~Doxorubicin 25mg/m2, d1, d15, IV; Vincristine 3mg/m2, d1, d15 IV; Dacarbazine 0.375mg/m2, d1, d15 IV
Study NCT06516250 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Virtual serious game GEMAS
Description: Implement and evaluate a virtual serious game designed to improve the learning and retention of clinical knowledge in medicine and nursing students and residents through the simulation of clinical cases in a hospital emergency environment.
Study NCT04876989 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: US-SGB
Description: Well trained pain physician performs all the ultrasound(US)-guided stellate ganglion block(SGB)s, who is not involved in evaluating study variables. Electrocardiography, noninvasive blood pressure, heart rate, and peripheral oxygen saturation were monitored for all patients before, while, and after conducting procedure. For US-guided SGB, patients are supine positioned, and skin preparation on injection site is done with chlorohexidine. Procedure is conducted under ultrasound guidance at C6 level. 5 ml of 1% mepivacaine is injected for the US-SGB group.
Study NCT04876989 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: US-TPVB
Description: Well trained pain physician performs all the ultrasound(US)-guided thoracic paravertebral block(SGB)s, who is not involved in evaluating study variables. Electrocardiography, noninvasive blood pressure, heart rate, and peripheral oxygen saturation were monitored for all patients before, while, and after conducting procedure. For US-guided TPVB, patients are prone positioned, and skin preparation on injection site is done with chlorohexidine. Procedure is conducted under ultrasound guidance at T2 paravertebral space. 10 ml of 1% mepivacaine is injected for the US-TPVB group.
Study NCT05693090 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tipifarnib
Description: Oral administration
Study NCT05693090 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Osimertinib
Description: Oral administration
Study NCT06382363 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: POC-cHbA1c testing
Description: The point-of-care HbA1c instrument employed in this study will be the Cobas b 101 (Roche Diagnostics, Switzerland) diagnostic test system. A capillary blood sample will be obtained by dermal puncture of a fingertip using a disposable lancet and resorbed in the specially marked area of the Cobas b 101 test disc. The disc will be inserted in the autoanalyzer. Test results displayed in both % and mmol/l will be available within 10 minutes.
Study NCT05896046 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR2554+ SHR1701
Description: SHR2554: 350mg/day, PO, twice a day. SHR1701: recommended dose from phase I trial, IV, over 30 minutes.
Study NCT05896046 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR-1701
Description: Phase I: 30-150 mg/kg, IV over 30 minutes. Phase II: recommended dose from phase I trial, IV over 30 minutes.
Study NCT06418776 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Intensive therapy
Description: Intensive chemotherapy courses (MEC, FLAG, FLAG-Ida, FLAG-Mito)
Study NCT06418776 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Low intensity therapy
Description: Low intensity therapy (Aza+Ven, Dac+Ven, LDARA-C+Ven)
Study NCT04476576 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Aerobic exercise (experimental)
Description: 3 times per week, 30 minutes each time. Entrance in heat: 8-10 min of joint mobility and / or the aerobic exercise in the main part at light intensity (OMNI 3-4) Main part: minimum 30 minutes, maximun 60 minutes. Intensity: moderate, guided by Talk Test and effort perception scale 5-6 OMNI. Type: aerobic, cycling or walking at home using a treadmill or exercise bike and / or cycling and walking outdoors according to the patient's possibilities and preferences. Return to calm: 5 min of aerobic physical activity of main part at mild intensity (OMNI 3-4), then static stretching. Pictures with each type of exercise will be offered and detailed explained.
Study NCT04476576 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Flexibility exercise (active comparator)
Description: Entrance in heat: 10 min of joint mobility. Main part: Minimum 30 minutes. Frequency: 3 times por week Intensity: The patient should be able to slowly stretch the muscle to a position of mild discomfort. Type: Static Stretch Time: 15-30 seconds 2 repetitions of each stretch Number of exercises: 12 . Pictures with each muscle group to exercise will be offered and detailed explained.
Study NCT06278922 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Seeking Safety + Signs of Safety toolkit
Description: Signs of Safety is a Deaf-accessible toolkit to be used with the Seeking Safety treatment protocol. Seeking Safety is a manualized, non-exposure-based, cognitive behavioral therapy for trauma and addiction.
Study NCT06278922 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Treatment as usual
Description: NDT therapists come from a wide variety of training backgrounds, but each works with their clients to build on their existing strengths and provide support as clients develop new strategies and behaviors for overcoming adversity.
Study NCT06473532 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: TEXT4HF
Description: In addition to usual care, participants in the intervention group will receive 5 TMs/week for 12 weeks at a time of their preference. Tailoring of the TMs is performed based on participants' responses to validated questionnaires (health beliefs scales, HF-knowledge scale, and self-efficacy about HF self-care scale), administered at baseline and 4 weeks. They will also receive an AHA HF discharge informational packet.
Study NCT06176248 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Triamcinolone Acetonide
Description: 1 injection of local anaesthetic (5 ml levobupivacaine 2.5 mg/mL) opposite the subscapular nerve, under ultrasound control, in a lateral decubitus or sitting position. Subsequently, they underwent Xray-controlled arthrodistension by injection of 1 ml of Triamcinolone Acetonide, combined with 10 ml of visipaque 270 contrast medium and 5 ml of Xylocaine.
Study NCT06176248 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: saline solution
Description: intramuscular injection of 1 ml saline under ultrasound control under the same conditions as the experimental group. Subsequently, they will undergo Xray-controlled arthrodistension under the same conditions as the experimental group
Study NCT04933500 — intervention group
Intervention type: DEVICE
Intervention: Whitacre spinal needle
Description: 25G Whitacre spinal needle
Study NCT05588440 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ONCT-808
Description: A single infusion of ONCT-808 autologous CAR-T cell infusion will be administered intravenously~Phase 1: Dose Escalation with bridging therapy as needed~Phase 2: Patients with LBCL or MCL will be enrolled into two separate dose expansion cohorts.
Study NCT05588440 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bridging Therapy
Description: Bridging therapy can be oral chemotherapy or IV radiotherapy/chemotherapy per institution's guidelines
Study NCT05362292 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tolterodine Tartrate ER
Description: Anticholinergic
Study NCT05362292 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mirabegron
Description: Beta-3-adrenergic agonist
Study NCT05362292 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: matching placebo pill
Study NCT06390956 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pirtobrutinib
Description: Administered once daily as an oral medication.
Study NCT04900636 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Telemedicine Arm
Description: Patients with DM1 ≥ 18 years of age, users of closed loop hybrid systems, assigned to a follow-up program using a telemedicine platform combined with face-to-face visits according to protocol.
Study NCT06324474 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hyaluronic acid
Description: Gengigel syringe containing 1ml of 0.8% HA
Study NCT06324474 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: scaling and root planning
Description: scaling and root planning using ultrasonic scaler
Study NCT04591496 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral change intervention;
Description: Behavioral change intervention: goal setting, regarding child's diet and parental feeding practices; self-monitoring, with observation and recording of the child's food intake and parental feeding practices; individualized feedback, based on preceding week monitoring and according to the defined objectives, regarding child's and parent's behaviors; modeling and direct suggestions by tailored parent figures; positive reinforcement associated to parents' accomplishment of the objectives; prompts, to remember the defined objectives and the main messages of the intervention.
Study NCT04591496 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Health Education
Description: Health education: provision of information about preschool children's nutrition guidelines, effective parental feeding practices, strategies to overcome food and feeding-related barriers, and steps to form healthy habits.
Study NCT04591496 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Health Education
Description: Health education: provision of information about preschool children's nutrition guidelines, effective parental feeding practices, strategies to overcome food and feeding-related barriers, and steps to form healthy habits.
Study NCT05507762 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: UC-MSCs
Description: Usage: The stem cell preparation in this study is used intravenously in the elbow.~Dose: The dose of stem cell injection in this clinical study is set at 1×10\^6/Kg/time per injection Duration: 5 injections per trial group for the entire duration of the course, at 1st treatment, 2-week, 4-week, 16-week, and 24-week respectively
Study NCT05507762 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Saline solution
Description: Usage: The saline solution in this study is used intravenously in the elbow. Dose: The dose of saline solution in this clinical study is set at 250ml/time per injection Duration: 5 injections per person for the entire duration of the course, at 1st treatment, 2-week, 4-week, 16-week, and 24-week respectively
Study NCT06360068 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sulfasalazine Tablets
Description: All subjects who meet the inclusion/exclusion criteria will be given sulfasalazine 750mg/dose, twice a day. The dosage will be increased to 1000mg/dose within one month, twice a day if the patient tolerates well.
Study NCT05195203 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HS-10353
Description: Single or multiple dose(s) of HS-10353
Study NCT05195203 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Single or multiple dose(s) of placebo
Study NCT06305221 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Opioid-free Analgesics (esketamine, dexmedetomidine)
Description: opioid free group: After infusion of a loading dose of dexmedetomidine, intravenous midazolam 2mg, propofol 2mg kg-1, esketamine 0.5 mg kg-1, rocuronium 0.6-1mg kg-1, and 3min after endotracheal intubation. Intravenous continuous infusion of propofol, esketamine and dexmedetomidine hydrochloride mixture (esketamine 50mg + dexmedetomidine hydrochloride 150 ug + 0.9% saline 50ml in the same 50ml syringe) 0.1ml kg-1 h-1-0.2 ml kg-1 h-1 (equivalent to esketamine 0.1-0.2mg kg-1 h-1; Dexmedetomidine hydrochloride 0.3-0.6 μ g kg-1 h-1) maintains a BIS value between 40-60, 10-20mg / time was added as appropriate.
Study NCT05900076 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Curettage for the evacuation of the product of conception
Description: The product of conception taken during the intervention will be recovered at Day 1
Study NCT06305221 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Opioid Anesthetics (sufentanil and remifentanil)
Description: Intravenous midazolam 2mg, propofol 2mg kg-1, sufentanyl 0.3-0.5 μ g kg-1, rocuronium 0.6-1mg kg-1,3min before endotracheal intubation. After successful endotracheal intubation, continuous intravenous infusion of propofol and remifentanil was started to maintain BIS values between 40-60, and rocuronium 10-20mg / time as appropriate. After the start of surgery, 10-20 μ g of sufentanil was added according to blood pressure and heart rate. At the end of the operation, 5mg and 50mg were injected before the end of the operation, and propofol and remifentanil were stopped at the end of the operation
Study NCT05007548 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ga68-Dolacga Injection
Description: Ga68-Dolacga Injection, 2.0±1.0 mCi, single dose, iv bolus
Study NCT05218057 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Ureteroscopic lithotripsy
Description: Ureteroscopic lithotripsy is one of the surgical procedure options for ureteric stone less than 1.5 cm. While many energy systems has been used for stone fragmentation during ureteroscopy, laser energy is the most commonly used approach for stone fragmentation.
Study NCT06194981 — intervention group
Intervention type: DRUG
Intervention: Oxaliplatin and capecitabine/ S-1 and capecitabine
Description: Drug: capecitabine: 1000 mg/m² bid, po, d1-14, oxaliplatin: 130mg/m², iv drip for 2h, d1; S-1: BSA\<1.25m², 40mg bid, 1.25m²≤BSA≤1.5m², 50mg bid, BSA>1.5m², 60mg bid, po, d1-14, oxaliplatin: 130mg/m², iv drip for 2h, d1
Study NCT06098196 — intervention group
Intervention type: DRUG
Intervention: Aminophyllin
Description: Patients will be observationally included in the Elveld TCI or Schnider TCI group and recevied or not Aminiophylline bolus. The TCI model, such as the aminophylline delivery or not, is chosen at anesthesiologist's discretion, as suggested in literature
Study NCT05467930 — intervention group
Intervention type: OTHER
Intervention: Survey
Description: Survey completion by the participant to collect information about health and social experience
Study NCT05467930 — intervention group
Intervention type: OTHER
Intervention: Medical History Review
Description: Review of the participant's medical history at New York Presbyterian/Columbia University Irving Medical Center
Study NCT05467930 — intervention group
Intervention type: OTHER
Intervention: Sample Collection
Description: Collection of nasal and blood samples
Study NCT06329999 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CMGV
Description: Initial treatment induction therapy: CMG+Vineclavone regimen Mitoxantrone liposomes 15mg/m2, iv, d1; Cytarabine 10mg/m2, H, q12h, d1-7; G-CSF starts at 5ug/kg, H, d0, WBC ≥ 30 × 109/L, stop G-CSF; Vinecla 100mg, 2200mg, 3400mg, d4-10. Every 4 weeks is a cycle, for a total of 2 cycles. For patients with CR/CRI/MLFS/PR in the first cycle, repeat this regimen for consolidation treatment once (the second course of treatment is Vineclavone 400mg d1-7).~Follow up treatment: Patients who meet the transplantation criteria will undergo hematopoietic stem cell transplantation, while those who do not undergo transplantation will continue to receive CMG+Vineclavone consolidation for 4-6 courses.
Study NCT06161155 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: Protein digestibility
Description: Two protein sources differing in digestiblity will be used in the dietary intervention to create a difference in protein flow into the large intestine, resulting in different levels of protein fermentation.~Participants will swallow an ingestible that senses biomarkers related to protein fermentation.
Study NCT05297656 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Instrument Assisted Soft Tissue Mobilization
Description: Instrument Assisted Soft Tissue Mobilization with graston tecnique and Home exercises programe
Study NCT05297656 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham Instrument Assisted Soft Tissue Mobilization
Description: Instrument Assisted Soft Tissue Mobilization to be applied superficially so it is not like a real graston tecnique and Home exercises programe
Study NCT05297656 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Home exercises programe
Description: Only Home exercises programe
Study NCT05297656 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Home exercises programe
Description: Only Home exercises programe
Study NCT05297656 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Home exercises programe
Description: Only Home exercises programe
Study NCT04968366 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Autologous dendritic cells pulsed with multiple neoantigen peptides.
Description: Each dosage of Dendritic Cells (DC) vaccine contains 2-10 million DC cells, loaded with 5-20 tumor neoantigen peptides. DC vaccine will be administered (i.d) around lymph nodes of the groin and Axillary at 2nd, 3rd, 4th, 7th and 11th week after the completion of concurrent Temozolomide chemoradiation. After 5 injections, the investigator will review subject's tolerance and compliance; and, decide whether to administer more DC vaccines up to 8 injections. For certain patients with good tolerance and clinical response of the DC vaccine, peripheral blood is extracted after completion of Temozolomide adjuvant chemotherapy to assess the patient's immune response. According to the result, investigators will decide whether to perform 1-2 more treatment cycles (5-8 injections/cycle) to strengthen the effectiveness
Study NCT04968366 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide adjuvant chemotherapy
Description: Temozolomide is administered as the standard-of-care adjuvant chemotherapy, in combination with the DC vaccines to treat the enrolled patients.
Study NCT04804930 — intervention group
Intervention type: PROCEDURE
Intervention: picture
Description: We will perform a non-invasive assessment of the scalp with a dermoscope by taking two standardized pictures on the frontal area and the occipital area in order to a blinded analysis of trichoscopic patterns
Study NCT05136157 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rapid-Acting Insulin
Description: 50 IU of rapid acting insulin taken by a 100 units (1ml) insulin syringe will be added to a 50 ml syringe containing normal saline (NS) to have a total volume of 50 ml with a concentration of 1 IU of insulin per 1 ml of NS
Study NCT04900766 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mitoxantrone Hydrochloride Liposome Injection
Description: 20 mg/m2, IV, on day 1 of each 21-day cycle (q3w).
Study NCT05441995 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cryotherapy
Description: Ice packs were applied in the buccal mucosa related to the tooth for 5 minutes after IANB administration
Study NCT05441995 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Cryotherapy
Description: Ice packs were applied in the buccal mucosa related to the tooth for 5 minutes after IANB administration
Study NCT05301543 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Experimental: Behavioral approach 1
Description: Includes changing sleep habits and cognitions around sleep from a mental level
Study NCT05301543 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Comparator: Behavioral approach 2
Description: Includes changing sleep habits and awarenes of sleep from a perception level
Study NCT04294355 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Artificial intelligence-Assisted colonoscopy
Description: Artificial intelligence-Assisted colonoscopy for detection of colonic polyp
Study NCT04294355 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Conventional colonoscopy
Description: Conventional colonoscopy
Study NCT04294355 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional colonoscopy
Description: Conventional colonoscopy
Study NCT04815200 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Copper Nickel titanium arch wire
Description: Patient will receive 0.014 round Copper Nickel titanium CuNiTi archwire and will be ligated using a ligature wire.
Study NCT06358716 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Complete Oral Nutrition Supplement 1
Description: Liquid formula produced by several food ingredients to provide a balance nutrient intake
Study NCT06358716 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Complete Oral Nutrition Supplement 2
Description: Liquid formula produced by several food ingredients to provide a balance nutrient intake